{"protocolSection": {"identificationModule": {"nctId": "NCT00412113", "orgStudyIdInfo": {"id": "A3841045"}, "organization": {"fullName": "Pfizer", "class": "INDUSTRY"}, "briefTitle": "A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk", "officialTitle": "A 6-Week, Prospective, Randomized, Double-Blind, Double-Dummy Phase IV Clinical Trial Designed to Evaluate the Efficacy of an Aggressive Multi-Risk Factor Management Strategy With Caduet (A3841045) Versus a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensive Subjects With Additional Risk Factors.", "acronym": "TOGETHER"}, "statusModule": {"statusVerifiedDate": "2021-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-12-13", "studyFirstSubmitQcDate": "2006-12-13", "studyFirstPostDateStruct": {"date": "2006-12-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-04-13", "resultsFirstSubmitQcDate": "2009-09-29", "resultsFirstPostDateStruct": {"date": "2009-11-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2021-01-26", "lastUpdatePostDateStruct": {"date": "2021-02-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "Director, Clinical Trial Disclosure Group", "oldOrganization": "Pfizer, Inc."}, "leadSponsor": {"name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia."}, "conditionsModule": {"conditions": ["Dyslipidemia", "Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 245, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Norvasc 5 mg", "type": "ACTIVE_COMPARATOR", "description": "Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.", "interventionNames": ["Drug: Amlodipine besylate"]}, {"label": "Caduet 10/20mg", "type": "EXPERIMENTAL", "description": "Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.", "interventionNames": ["Drug: Amlodipine besylate/atorvastatin calcium single pill combination"]}, {"label": "Norvasc 10 mg", "type": "ACTIVE_COMPARATOR", "description": "Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.", "interventionNames": ["Drug: Amlodipine besylate"]}, {"label": "Caduet 5/20mg", "type": "EXPERIMENTAL", "description": "Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .", "interventionNames": ["Drug: Amlodipine besylate/atorvastatin calcium single pill combination"]}], "interventions": [{"type": "DRUG", "name": "Amlodipine besylate", "description": "Amlodipine besylate 5 mg", "armGroupLabels": ["Norvasc 5 mg"]}, {"type": "DRUG", "name": "Amlodipine besylate/atorvastatin calcium single pill combination", "description": "Amlodipine/atorvastatin single pill combination 10/20 mg", "armGroupLabels": ["Caduet 10/20mg"]}, {"type": "DRUG", "name": "Amlodipine besylate", "description": "Amlodipine besylate 10 mg", "armGroupLabels": ["Norvasc 10 mg"]}, {"type": "DRUG", "name": "Amlodipine besylate/atorvastatin calcium single pill combination", "description": "Amlodipine/atorvastatin single pill combination 5/20 mg", "armGroupLabels": ["Caduet 5/20mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6", "description": "Number of subjects reaching dual goal of systolic blood pressure \\<140 millimeters of mercury (mmHg) and diastolic blood pressue of \\<90 mmHg and low density lipoprotein-cholesterol(LDL-C) \\<100 milligrams per deciliter(mg/dL)", "timeFrame": "Week 6"}, {"measure": "Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk", "description": "Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \\[MI\\] or CHD death) are calculations based on total point score (range less than negative 3 \\[best\\] to greater than or equal to 14 \\[worst\\] for men; less than or equal to negative 2 \\[best\\] and greater than or equal to 17 \\[worst\\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.", "timeFrame": "Week 6, baseline"}], "secondaryOutcomes": [{"measure": "Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4", "description": "Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of \\<140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal \\<100 mg/dL at Week 4.", "timeFrame": "Week 4"}, {"measure": "Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.", "description": "Subjects achieving both JNC-7 blood pressure goal of \\<140/90 mmHg and NCEP/ATP III LDL-C goal \\<130 mg/dL at Week 4.", "timeFrame": "Week 4"}, {"measure": "Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.", "description": "Subjects achieving both JNC-7 blood pressure goal of \\<140/90 mmHg and NCEP/ATP III LDL-C goal \\<130 mg/dL at Week 6.", "timeFrame": "Week 6"}, {"measure": "Subjects With LDL-C < 100 mg/dL at Week 4", "description": "Subjects Who achieve a goal of LDL-C \\< 100 mg/dL at Week 4.", "timeFrame": "Week 4"}, {"measure": "Subjects With LDL-C < 100 mg/dL at Week 6", "description": "Subjects Who achieve a goal of LDL-C \\< 100 mg/dL at Week 6.", "timeFrame": "Week 6"}, {"measure": "Subjects With BP < 140/90 mmHg at Week 4", "description": "Subjects achieving BP goal of \\<140/90 mmHg at week 4", "timeFrame": "Week 4"}, {"measure": "Subjects With BP < 140/90 mmHg at Week 6", "description": "Subjects achieving BP goal of \\<140/90 mmHg at week 6", "timeFrame": "Week 6"}, {"measure": "Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).", "description": "Mean at observation minus mean at baseline", "timeFrame": "Week 4, baseline"}, {"measure": "Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)", "description": "Mean at observation minus mean at baseline", "timeFrame": "Week 4, baseline"}, {"measure": "Change From Baseline to Week 4 in Pulse Rate", "description": "Mean at observation minus mean at baseline measured in beats per minute (bpm).", "timeFrame": "Week 4, baseline"}, {"measure": "Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)", "description": "Mean change at observation minus mean baseline.", "timeFrame": "Week 6, baseline"}, {"measure": "Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)", "description": "Change from mean at observation minus mean at baseline", "timeFrame": "Week 6, baseline"}, {"measure": "Change From Baseline to Week 6 in Pulse Rate", "description": "Mean at observation minus mean at baseline", "timeFrame": "Week 6, baseline"}, {"measure": "Change From Baseline in LDL at Week 4.", "description": "Change: mean of observation minus mean at baseline.", "timeFrame": "Week 4, baseline"}, {"measure": "Change From Baseline in High Density Lipoprotein (HDL) at Week 4.", "description": "Mean change at observation minus baseline.", "timeFrame": "Week 4, baseline"}, {"measure": "Change in Total Cholesterol (TC) From Baseline to Week 4.", "description": "Mean change at observation minus baseline.", "timeFrame": "Week 4, baseline"}, {"measure": "Change From Baseline in Triglycerides (TG) to Week 4.", "description": "Mean change at observation minus baseline", "timeFrame": "Week 4, baseline"}, {"measure": "Change From Baseline in LDL at Week 6.", "description": "Mean change at observation minus baseline.", "timeFrame": "Week 6, baseline"}, {"measure": "Change From Baseline in HDL at Week 6.", "description": "Mean change at observation minus baseline.", "timeFrame": "Week 6, baseline"}, {"measure": "Change From Baseline in Total Cholesterol (TC) to Week 6.", "description": "Mean change at observation minus baseline.", "timeFrame": "Week 6, baseline"}, {"measure": "Change From Baseline in Triglycerides (TG) at Week 6.", "description": "Mean change at observation minus mean baseline.", "timeFrame": "Week 6 , baseline"}, {"measure": "Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.", "description": "Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 \\[best\\] to greater than or equal to 14 \\[worst\\] for men; less than or equal to negative 2 \\[best\\] and greater than or equal to 17 \\[worst\\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.", "timeFrame": "Week 4, baseline"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and who also have 3 additional cardiovascular risk factors, including dyslipidemia.\n\nExclusion Criteria:\n\n* Subjects who are taking the following prohibited medications within 14 days of screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, \\>3 antihypertensive agents (including Norvasc)\n* Subjects that have not been on a stable dose of Norvasc for at least 4 weeks\n* Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular Disease (PVD)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Pfizer CT.gov Call Center", "affiliation": "Pfizer", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Pfizer Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Pfizer Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35216", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Pfizer Investigational Site", "city": "Birmingham", "state": "Alabama", "zip": "35234", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Pfizer Investigational Site", "city": "Mesa", "state": "Arizona", "zip": "85206", "country": "United States", "geoPoint": {"lat": 33.42227, "lon": -111.82264}}, {"facility": "Pfizer Investigational Site", "city": "Garden Grove", "state": "California", "zip": "92843", "country": "United States", "geoPoint": {"lat": 33.77391, "lon": -117.94145}}, {"facility": "Pfizer Investigational Site", "city": "Mission Viejo", "state": "California", "zip": "92692", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Pfizer Investigational Site", "city": "Rancho Santa Margarita", "state": "California", "zip": "92688", "country": "United States", "geoPoint": {"lat": 33.64086, "lon": -117.6031}}, {"facility": "Pfizer Investigational Site", "city": "Torrance", "state": "California", "zip": "90502", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Pfizer Investigational Site", "city": "Gainesville", "state": "Florida", "zip": "32605", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Pfizer Investigational Site", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Pfizer Investigational Site", "city": "Melbourne", "state": "Florida", "zip": "32935", "country": "United States", "geoPoint": {"lat": 28.08363, "lon": -80.60811}}, {"facility": "Pfizer Investigational Site", "city": "Miami", "state": "Florida", "zip": "33176", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Pfizer Investigational Site", "city": "Safety Harbor", "state": "Florida", "zip": "34695", "country": "United States", "geoPoint": {"lat": 27.99085, "lon": -82.69316}}, {"facility": "Pfizer Investigational Site", "city": "Saint Petersburg", "state": "Florida", "zip": "33701", "country": "United States", "geoPoint": {"lat": 27.77086, "lon": -82.67927}}, {"facility": "Pfizer Investigational Site", "city": "Augusta", "state": "Georgia", "zip": "30904", "country": "United States", "geoPoint": {"lat": 33.47097, "lon": -81.97484}}, {"facility": "Pfizer Investigational Site", "city": "Tucker", "state": "Georgia", "zip": "30084", "country": "United States", "geoPoint": {"lat": 33.85455, "lon": -84.21714}}, {"facility": "Pfizer Investigational Site", "city": "South Bend", "state": "Indiana", "zip": "46601", "country": "United States", "geoPoint": {"lat": 41.68338, "lon": -86.25001}}, {"facility": "Pfizer Investigational Site", "city": "Erlanger", "state": "Kentucky", "zip": "41018", "country": "United States", "geoPoint": {"lat": 39.01673, "lon": -84.60078}}, {"facility": "Pfizer Investigational Site", "city": "Auburn", "state": "Maine", "zip": "04210", "country": "United States", "geoPoint": {"lat": 44.09785, "lon": -70.23117}}, {"facility": "Pfizer Investigational Site", "city": "Warren", "state": "Michigan", "zip": "48091", "country": "United States", "geoPoint": {"lat": 42.49042, "lon": -83.01306}}, {"facility": "Pfizer Investigational Site", "city": "Minneapolis", "state": "Minnesota", "zip": "55404", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Pfizer Investigational Site", "city": "Chesterfield", "state": "Missouri", "zip": "63017", "country": "United States", "geoPoint": {"lat": 38.66311, "lon": -90.57707}}, {"facility": "Pfizer Investigational Site", "city": "Florissant", "state": "Missouri", "zip": "63031", "country": "United States", "geoPoint": {"lat": 38.78922, "lon": -90.32261}}, {"facility": "Pfizer Investigational Site", "city": "Omaha", "state": "Nebraska", "zip": "68116-2004", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Pfizer Investigational Site", "city": "Henderson", "state": "Nevada", "zip": "89014", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "Pfizer Investigational Site", "city": "Henderson", "state": "Nevada", "zip": "89015", "country": "United States", "geoPoint": {"lat": 36.0397, "lon": -114.98194}}, {"facility": "Pfizer Investigational Site", "city": "Belvidere", "state": "New Jersey", "zip": "07823", "country": "United States", "geoPoint": {"lat": 40.82982, "lon": -75.07767}}, {"facility": "Pfizer Investigational Site", "city": "Bridgewater", "state": "New Jersey", "zip": "08807", "country": "United States", "geoPoint": {"lat": 40.60079, "lon": -74.64815}}, {"facility": "Pfizer Investigational Site", "city": "Clifton", "state": "New Jersey", "zip": "07013", "country": "United States", "geoPoint": {"lat": 40.85843, "lon": -74.16376}}, {"facility": "Pfizer Investigational Site", "city": "Elizabeth", "state": "New Jersey", "zip": "07202", "country": "United States", "geoPoint": {"lat": 40.66399, "lon": -74.2107}}, {"facility": "Pfizer Investigational Site", "city": "Hillsborough", "state": "New Jersey", "zip": "08844", "country": "United States", "geoPoint": {"lat": 40.4776, "lon": -74.62682}}, {"facility": "Pfizer Investigational Site", "city": "Trenton", "state": "New Jersey", "zip": "08618", "country": "United States", "geoPoint": {"lat": 40.21705, "lon": -74.74294}}, {"facility": "Pfizer Investigational Site", "city": "Brooklyn", "state": "New York", "zip": "11229", "country": "United States", "geoPoint": {"lat": 40.6501, "lon": -73.94958}}, {"facility": "Pfizer Investigational Site", "city": "Buffalo", "state": "New York", "zip": "14209", "country": "United States", "geoPoint": {"lat": 42.88645, "lon": -78.87837}}, {"facility": "Pfizer Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45219", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Pfizer Investigational Site", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Pfizer Investigational Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73103", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Pfizer Investigational Site", "city": "Tulsa", "state": "Oklahoma", "zip": "74136", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Pfizer Investigational Site", "city": "Bensalem", "state": "Pennsylvania", "zip": "19020", "country": "United States", "geoPoint": {"lat": 40.10455, "lon": -74.95128}}, {"facility": "Pfizer Investigational Site", "city": "Lansdale", "state": "Pennsylvania", "zip": "19446", "country": "United States", "geoPoint": {"lat": 40.2415, "lon": -75.28379}}, {"facility": "Pfizer Investigational Site", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19146", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Pfizer Investigational Site", "city": "Providence", "state": "Rhode Island", "zip": "02904", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Pfizer Investigational Site", "city": "Goose Creek", "state": "South Carolina", "zip": "29445", "country": "United States", "geoPoint": {"lat": 32.98101, "lon": -80.03259}}, {"facility": "Pfizer Investigational Site", "city": "Mount Pleasant", "state": "South Carolina", "zip": "29464", "country": "United States", "geoPoint": {"lat": 32.79407, "lon": -79.86259}}, {"facility": "Pfizer Investigational Site", "city": "Bristol", "state": "Tennessee", "zip": "37620", "country": "United States", "geoPoint": {"lat": 36.59511, "lon": -82.18874}}, {"facility": "Pfizer Investigational Site", "city": "Kingsport", "state": "Tennessee", "zip": "37660", "country": "United States", "geoPoint": {"lat": 36.54843, "lon": -82.56182}}, {"facility": "Pfizer Investigational Site", "city": "Dallas", "state": "Texas", "zip": "75235", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Pfizer Investigational Site", "city": "Houston", "state": "Texas", "zip": "77030-2324", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Pfizer Investigational Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Pfizer Investigational Site", "city": "San Antonio", "state": "Texas", "zip": "78238", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Pfizer Investigational Site", "city": "Chesapeake", "state": "Virginia", "zip": "23320", "country": "United States", "geoPoint": {"lat": 36.81904, "lon": -76.27494}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "To obtain contact information for a study center near you, click here.", "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3841045&StudyName=A%20Multi-Risk%20Factor%20Strategy%20Vs%20A%20Guideline-Based%20Approach%20In%20Achieving%20Blood%20Pressure%20%26%20Lipid%20Goals%20In%20Hypertensives%20At%20Extra%20Risk"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study enrolled 244 evaluable subjects. Drug treatments were used prior to the start of the study in all subjects in the Caduet and therapeutic lifestyle changes (TLC) group and the Norvasc and TLC group. Amlodipine was used by all subjects prior to entry. The study's four arms are two groups, each with drug group and matching placebo.", "groups": [{"id": "FG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "FG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "15-January-2007", "numSubjects": "123"}, {"groupId": "FG001", "comment": "15-January-2007", "numSubjects": "122"}]}, {"type": "Received Treatment", "achievements": [{"groupId": "FG000", "comment": "One subject assigned to Norvasc and TLC did not receive treatment and was excluded from all analyses", "numSubjects": "122"}, {"groupId": "FG001", "numSubjects": "122"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "comment": "15-April-2008", "numSubjects": "111"}, {"groupId": "FG001", "comment": "15-April-2008", "numSubjects": "107"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "15"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "15"}]}, {"type": "did not receive treatment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "BG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "122"}, {"groupId": "BG001", "value": "122"}, {"groupId": "BG002", "value": "244"}]}], "measures": [{"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "18 to 64 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "97"}, {"groupId": "BG002", "value": "192"}]}]}, {"title": "> or = to 65 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "52"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "56"}, {"groupId": "BG001", "value": "65"}, {"groupId": "BG002", "value": "121"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "66"}, {"groupId": "BG001", "value": "57"}, {"groupId": "BG002", "value": "123"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6", "description": "Number of subjects reaching dual goal of systolic blood pressure \\<140 millimeters of mercury (mmHg) and diastolic blood pressue of \\<90 mmHg and low density lipoprotein-cholesterol(LDL-C) \\<100 milligrams per deciliter(mg/dL)", "populationDescription": "Full analysis set (FAS) is all randomized subjects who take at least one dose of study drug and and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "80"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the BP(\\< 140/90 mmHg) and LDL goal (\\< 100mg/dL) at Week 6.\n\nWith \\~120 in each treatment arm, planned power was at least 90% to detect a difference between treatments, assuming 35% in the Caduet and 15% in the Norvasc arm achieving BP \\<140/90 mmHg and LDL \\<100 mg/dL and using a chi-square test with 0.05 two-sided significance level.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "There was only one primary endpoint and the p-value was not adjusted for comparison.", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "19.03", "ciPctValue": "95", "ciLowerLimit": "9.14", "ciUpperLimit": "39.63"}]}, {"type": "SECONDARY", "title": "Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4", "description": "Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of \\<140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal \\<100 mg/dL at Week 4.", "populationDescription": "Full analysis set. All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "116"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "73"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the blood pressure (\\< 140/90 mmHg) and LDL-goal (\\<100 mg/dL) at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analysis", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "31.39", "ciPctValue": "95", "ciLowerLimit": "12.61", "ciUpperLimit": "78.09"}]}, {"type": "SECONDARY", "title": "Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.", "description": "Subjects achieving both JNC-7 blood pressure goal of \\<140/90 mmHg and NCEP/ATP III LDL-C goal \\<130 mg/dL at Week 4.", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "85"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the blood pressure (\\< 140/90 mmHg) and LDL-goal (\\<130mg/dL) at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "5.2", "ciPctValue": "95", "ciLowerLimit": "2.93", "ciUpperLimit": "9.24"}]}, {"type": "SECONDARY", "title": "Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.", "description": "Subjects achieving both JNC-7 blood pressure goal of \\<140/90 mmHg and NCEP/ATP III LDL-C goal \\<130 mg/dL at Week 6.", "populationDescription": "Full analysis set (FAS).", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45"}, {"groupId": "OG001", "value": "90"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving both the blood pressure (\\< 140/90 mmHg) and LDL-goal (\\<130mg/dL) at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "5.14", "ciPctValue": "95", "ciLowerLimit": "2.89", "ciUpperLimit": "9.11"}]}, {"type": "SECONDARY", "title": "Subjects With LDL-C < 100 mg/dL at Week 4", "description": "Subjects Who achieve a goal of LDL-C \\< 100 mg/dL at Week 4.", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "96"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving (\\<100mg/DL) at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "65.51", "ciPctValue": "95", "ciLowerLimit": "27.10", "ciUpperLimit": "158.34"}]}, {"type": "SECONDARY", "title": "Subjects With LDL-C < 100 mg/dL at Week 6", "description": "Subjects Who achieve a goal of LDL-C \\< 100 mg/dL at Week 6.", "populationDescription": "Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "99"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving LDL-goal (\\<100mg/DL) at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "42.04", "ciPctValue": "95", "ciLowerLimit": "19.42", "ciUpperLimit": "90.99"}]}, {"type": "SECONDARY", "title": "Subjects With BP < 140/90 mmHg at Week 4", "description": "Subjects achieving BP goal of \\<140/90 mmHg at week 4", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 4", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "117"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "84"}, {"groupId": "OG001", "value": "87"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving blood pressure (\\< 140/90 mmHg)at Week 4", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.785", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.09", "ciPctValue": "95", "ciLowerLimit": "0.60", "ciUpperLimit": "1.98"}]}, {"type": "SECONDARY", "title": "Subjects With BP < 140/90 mmHg at Week 6", "description": "Subjects achieving BP goal of \\<140/90 mmHg at week 6", "populationDescription": "Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Week 6", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "94"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the percentage of patients achieving blood pressure (\\< 140/90 mmHg) at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.171", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "Cochran-Mantel-Haenszel", "paramType": "Odds Ratio (OR)", "paramValue": "1.55", "ciPctValue": "95", "ciLowerLimit": "0.83", "ciUpperLimit": "2.88"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).", "description": "Mean at observation minus mean at baseline", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.6", "spread": "12.1"}, {"groupId": "OG001", "value": "-1.5", "spread": "11.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in systolic blood pressure at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.585", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "0.76", "ciPctValue": "95", "ciLowerLimit": "-1.97", "ciUpperLimit": "3.48"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)", "description": "Mean at observation minus mean at baseline", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.5", "spread": "7.7"}, {"groupId": "OG001", "value": "-1.2", "spread": "8.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in diastolic blood pressure at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "> 0.999", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-0.00", "ciPctValue": "95", "ciLowerLimit": "-2.01", "ciUpperLimit": "2.01"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4 in Pulse Rate", "description": "Mean at observation minus mean at baseline measured in beats per minute (bpm).", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "8.2"}, {"groupId": "OG001", "value": "-0.9", "spread": "8.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in pulse rate at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.363", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-0.90", "ciPctValue": "95", "ciLowerLimit": "-2.83", "ciUpperLimit": "1.04"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)", "description": "Mean change at observation minus mean baseline.", "populationDescription": "Full analysis set: all randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.0", "spread": "12.6"}, {"groupId": "OG001", "value": "-4.0", "spread": "11.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in systolic blood pressure at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.020", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS means", "paramValue": "-3.25", "ciPctValue": "95", "ciLowerLimit": "-5.99", "ciUpperLimit": "-0.51"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)", "description": "Change from mean at observation minus mean at baseline", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.1", "spread": "7.1"}, {"groupId": "OG001", "value": "-1.7", "spread": "8.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in diastolic blood pressure at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.351", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-0.87", "ciPctValue": "95", "ciLowerLimit": "-2.71", "ciUpperLimit": "0.97"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 6 in Pulse Rate", "description": "Mean at observation minus mean at baseline", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.9", "spread": "8.1"}, {"groupId": "OG001", "value": "1.1", "spread": "9.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in mean change from baseline in pulse rate at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.922", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "0.10", "ciPctValue": "95", "ciLowerLimit": "-1.91", "ciUpperLimit": "2.11"}]}, {"type": "SECONDARY", "title": "Change From Baseline in LDL at Week 4.", "description": "Change: mean of observation minus mean at baseline.", "populationDescription": "Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.5", "spread": "23.0"}, {"groupId": "OG001", "value": "-47.8", "spread": "24.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in LDL at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-49.30", "ciPctValue": "95", "ciLowerLimit": "-54.68", "ciUpperLimit": "-43.91"}]}, {"type": "SECONDARY", "title": "Change From Baseline in High Density Lipoprotein (HDL) at Week 4.", "description": "Mean change at observation minus baseline.", "populationDescription": "Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.6", "spread": "5.8"}, {"groupId": "OG001", "value": "0.6", "spread": "8.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in HDL at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.739", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "difference in LS Means", "paramValue": "-0.30", "ciPctValue": "95", "ciLowerLimit": "-2.07", "ciUpperLimit": "1.47"}]}, {"type": "SECONDARY", "title": "Change in Total Cholesterol (TC) From Baseline to Week 4.", "description": "Mean change at observation minus baseline.", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "spread": "23.5"}, {"groupId": "OG001", "value": "-55.9", "spread": "26.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in TC at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-57.9", "ciPctValue": "95", "ciLowerLimit": "-64.02", "ciUpperLimit": "51.81"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Triglycerides (TG) to Week 4.", "description": "Mean change at observation minus baseline", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.4", "spread": "73.2"}, {"groupId": "OG001", "value": "-45.7", "spread": "62.8"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in TG at Week 4.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-47.27", "ciPctValue": "95", "ciLowerLimit": "-63.37", "ciUpperLimit": "-31.16"}]}, {"type": "SECONDARY", "title": "Change From Baseline in LDL at Week 6.", "description": "Mean change at observation minus baseline.", "populationDescription": "Full analysis set. All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.3", "spread": "24.8"}, {"groupId": "OG001", "value": "-49.2", "spread": "24.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in LDL at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-51.21", "ciPctValue": "95", "ciLowerLimit": "-56.88", "ciUpperLimit": "-45.55"}]}, {"type": "SECONDARY", "title": "Change From Baseline in HDL at Week 6.", "description": "Mean change at observation minus baseline.", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2", "spread": "8.2"}, {"groupId": "OG001", "value": "0.4", "spread": "8.2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in HDL at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.329", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-1.02", "ciPctValue": "95", "ciLowerLimit": "-3.07", "ciUpperLimit": "1.03"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Cholesterol (TC) to Week 6.", "description": "Mean change at observation minus baseline.", "populationDescription": "Full analysis set (FAS) All randomized subjects who take at least one dose of study drug and have any post-baseline efficacy assessments.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.7", "spread": "23.8"}, {"groupId": "OG001", "value": "-56.8", "spread": "28.4"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline in TC at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-62.07", "ciPctValue": "95", "ciLowerLimit": "-68.49", "ciUpperLimit": "-55.65"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Triglycerides (TG) at Week 6.", "description": "Mean change at observation minus mean baseline.", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Week 6 , baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11.6", "spread": "115.3"}, {"groupId": "OG001", "value": "-42.6", "spread": "67.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change in TG from baseline in at Week 6.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-53.95", "ciPctValue": "95", "ciLowerLimit": "-77.61", "ciUpperLimit": "-30.29"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.", "description": "Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 \\[best\\] to greater than or equal to 14 \\[worst\\] for men; less than or equal to negative 2 \\[best\\] and greater than or equal to 17 \\[worst\\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.", "populationDescription": "Full analysis set (FAS). All randomized subjects who took study drug and had at least one post-baseline efficacy assessment comprised the FAS.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on scale", "timeFrame": "Week 4, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "2.5"}, {"groupId": "OG001", "value": "-2.8", "spread": "3.3"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in mean change from baseline to Week 4 in Framingham predicted absolute 10-year risk.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-2.4", "ciPctValue": "95", "ciLowerLimit": "-3.1", "ciUpperLimit": "-1.7"}]}, {"type": "PRIMARY", "title": "Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk", "description": "Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \\[MI\\] or CHD death) are calculations based on total point score (range less than negative 3 \\[best\\] to greater than or equal to 14 \\[worst\\] for men; less than or equal to negative 2 \\[best\\] and greater than or equal to 17 \\[worst\\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.", "populationDescription": "The full analysis set of all randomized subjects who took at least one dose of study drug and had any post-baseline efficacy assessment", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "score on scale", "timeFrame": "Week 6, baseline", "groups": [{"id": "OG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks."}, {"id": "OG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "115"}, {"groupId": "OG001", "value": "118"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.1", "spread": "2.9"}, {"groupId": "OG001", "value": "-2.9", "spread": "3.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: There is no difference between the two treatment management strategies in the mean change from baseline to Week 6 in Framingham predicted absolute 10-year risk.", "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<0.001", "pValueComment": "No adjustment for p-value for secondary analyses", "statisticalMethod": "ANCOVA", "paramType": "Difference in LS Means", "paramValue": "-2.8", "ciPctValue": "95", "ciLowerLimit": "-3.5", "ciUpperLimit": "-2.1"}]}]}, "adverseEventsModule": {"frequencyThreshold": "2", "eventGroups": [{"id": "EG000", "title": "Norvasc + TLC", "description": "Blinded Norvasc (amlodipine) 5 to 10 milligram (mg) and matching Caduet placebo dosed once daily along with Therapeutic Lifestyle Changes (TLC) for 6 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 122, "otherNumAffected": 16, "otherNumAtRisk": 122}, {"id": "EG001", "title": "Caduet + TLC", "description": "Blinded Caduet (amlodipine besylate/atorvastatin calcium) 5/20 to 10/20 mg and matching Norvasc placebo dosed once daily along with TLC for 6 weeks.", "seriousNumAffected": 0, "seriousNumAtRisk": 122, "otherNumAffected": 7, "otherNumAtRisk": 122}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA v11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 122}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 122}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA v11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 122}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 122}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA v11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 122}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 122}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of \\< 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), \\< 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential info other than study results."}, "pointOfContact": {"title": "Pfizer ClinicalTrials.gov Call Center", "organization": "Pfizer, Inc.", "email": "ClinicalTrials.govCallCenter@pfizer.com", "phone": "1-800-718-1021"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000050171", "term": "Dyslipidemias"}], "ancestors": [{"id": "D000052439", "term": "Lipid Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "relevance": "LOW"}, {"id": "M26181", "name": "Dyslipidemias", "asFound": "Dyslipidemia", "relevance": "HIGH"}, {"id": "M3724", "name": "Aggression", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M27029", "name": "Lipid Metabolism Disorders", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000002136", "term": "Calcium, Dietary"}, {"id": "D000017311", "term": "Amlodipine"}, {"id": "D000069059", "term": "Atorvastatin"}, {"id": "D000002118", "term": "Calcium"}], "ancestors": [{"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000050071", "term": "Bone Density Conservation Agents"}, {"id": "D000000924", "term": "Anticholesteremic Agents"}, {"id": "D000000960", "term": "Hypolipidemic Agents"}, {"id": "D000000963", "term": "Antimetabolites"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000057847", "term": "Lipid Regulating Agents"}, {"id": "D000019161", "term": "Hydroxymethylglutaryl-CoA Reductase Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000014665", "term": "Vasodilator Agents"}], "browseLeaves": [{"id": "M5381", "name": "Calcium", "asFound": "Double-blind", "relevance": "HIGH"}, {"id": "M5398", "name": "Calcium, Dietary", "asFound": "Double-blind", "relevance": "HIGH"}, {"id": "M351", "name": "Atorvastatin", "asFound": "General", "relevance": "HIGH"}, {"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M223699", "name": "Amlodipine, atorvastatin drug combination", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M4243", "name": "Anticholesteremic Agents", "relevance": "LOW"}, {"id": "M4278", "name": "Hypolipidemic Agents", "relevance": "LOW"}, {"id": "M4281", "name": "Antimetabolites", "relevance": "LOW"}, {"id": "M28883", "name": "Lipid Regulating Agents", "relevance": "LOW"}, {"id": "M21155", "name": "Hydroxymethylglutaryl-CoA Reductase Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "Lipd", "name": "Lipid Regulating Agents"}, {"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}]}}, "hasResults": true}